Oncolytics: preclinical data show synergistic immunotherapeutic effects of Pelareorep radiotherapy

0

(RTTNews) – Oncolytics Biotech Inc. (ONCY, ONC.TO) announced preclinical data demonstrating the synergistic immunotherapeutic effects of pelareorep in combination with radiotherapy in a mouse cancer model.

The preclinical studies featured in the poster evaluated various therapeutic combinations of pelareorep, ionizing radiation, and anti-PD-1 therapy in mice with two bilateral tumors, each located subcutaneously (under the skin) of a different side of the body.

Radiation therapy and / or pelareorep treatment were administered locally to one tumor, while the second tumor (noted abscopal tumor) was not directly exposed to either therapy. Anti-PD-1 therapy was administered systemically.

The results showed that in primary tumors, pelareorep monotherapy resulted in a numerical increase in the number of infiltrating anticancer CD8 + T cells, which reached statistical significance when combined with radiotherapy.

In abscopal tumors, pelareorep monotherapy and pelareorep-radiation combination therapy led to a statistically significant increase in infiltrating anticancer CD8 + T cells. This effect was not observed with radiotherapy as monotherapy, neither in primary tumors nor in abscopal tumors.

Local administration of radiotherapy alone and the pelareorep-radiotherapy combination in primary tumors significantly improved survival compared to untreated controls.

Compared with radiotherapy as monotherapy, the pelareorep-radiotherapy combination led to a numerical increase in survival, which reached statistical significance when anti-PD-1 treatment was added to the treatment regimen.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


Source link

Leave A Reply

Your email address will not be published.